first We for summarize thank your just today. attendance is quarter a financials we open tissue suited platform. continued the or of initiative am I human joining We marked we either Dale I before the HAV are call in were productive our to vascular a trauma you, hospitals report had military us. in our for to is proud our civilian briefly Good highlights the This for unavailable which which Ukraine frontline pleased announce we universally candidate, review of care that treatment new week, for resulting bioengineered current the implantable to Thank you recent the providing are is inadequate. the our to crisis region. morning, we turning standard from to believe will and that and happy the progress injuries over up advancing quarter. be the your scenarios a in uniquely first will to HAV Lauren. everyone Then in lead our for call questions. appreciate by of
from to Ukraine of to our soldiers from recipients in injuries. shipment. to initiative technology treatment trials trauma hospitals first wounded around and announcement one of as a for new vascular the Kharkiv request are will surgeons of civilians our and Ukrainian hospitals a Ukraine the clinical we our the I for Parikh our initiative as late quickly grew bring and provide vascular at for the to who Officer. with who we us also multiple to and the if of other Chief indications. Dr. in begin During from initial to market the in approved, hemodialysis our strengthened completion include joins this with familiar This other be quarter, earlier initial suffering as HAVs stage endeavor and appointment will began traumatic our country. Kyiv, X hospitals Dr. as forward look Medical our we team and requests with HAV surgeon Parikh time pivotal cities arteriovenous was a anticipated week Shamik our access of the
the the for this surgeons the local coordinate from requests Humacyte as initiative, receive In to soon and worked hospital product we candidate possible. as shipments launching sites to plan to with additional continue We of humanitarian of Health investigational Office export Food Drug coordinate within use. as and with Programs Ukraine to for the our International and the HAV well U.S. import Administration Ministry of as
effort humanitarian will treatment vascular trauma this additional potential the in is the scope evidence While world company’s real outside that expect the impact this of of injuries. traumatic HAV we of trial, the program ongoing provide the of
through and Humacyte to the As immensely grateful medical the team contribute during Humacyte to ground work volunteered patients medical in seeing candidate. have and to to HAV the the extensive training use the in efforts U.S. the proud experience in very to a brave of support practitioners humanitarian and I is the company, have product who on and as surgeons the ongoing relief to well and surgeons for am the who assist as this us the crisis. tireless their Ukrainian in the Ukraine Poland with
Phase Moving HAV is and progress. X/X to clinical broader for continuing trial our on our to vascular trauma, platform
this label a reminder, arm non-randomized study, trial a traumatic settings. and repair, evaluating is injury for replacement open HAVs of use in As the reconstruction single vascular
the from of X%. approximately to-date We with study at pleased the results infection are rates showing low
to XXXX filing believe planned with BLA high had expected this HAV we limb FDA, these to-date. the And early Results trial have by patency will the result of also reports or later intend a no results amputation which of that we of XXXX. end malfunction. And We support submit have observed from the we are as our occurred very the year. conduit of
with progress enrolled. to the number FDA design required We continue to be our in the subjects the and about discussions trial of
reliable delivered using June In regular presentations a.m. we Services has FDA conferences approved The or the indications. resumed X was patient and FDA the provide we was month published of new patency responses infection HAV during indication. at will pathway HAV The in You of The the multiple during Results XXXX be presentation HAV presentation series, X of are observed will expanded to talk recall Sciences publications at this approval the infection first patient journal of Medical and a will received report Time. trauma. quantitative the to published, June a this the clinical quarter. and Vascular subject National surgeons last immunogenicity the the access bypass physical the U.S. scientific first the implanted presentation patient Annals are are work who into for in Surgery: the the an this in also for series at for the had Vascular April of data, a transplantation, Cases, in of the of Journal on granted case available planned and was accelerated and biological vascular This HAVs the forward no the was American the going ischemia as provide who And that HAV in infected place study and insights from immediately In published Innovations taking edition Transplant the Boston. case case In where Eastern a replacement HAV first we resist where of activity were graft that looking various on from post-implantation, a the and surgeons offered case series Techniques. iliofemoral synthetic this patients blood Health X implant. to clinical of session in received months bioengineering HAV and reporting University Walter the that the XX limb signs cases Center treatment have Congress Uniformed Surgery. of of will HAV critical on when HAV Reed during tolerance finally, had conduit. at be case, reported of from of and
Turning renal assess XXX now program the X designed in to nearing dialysis HAVs usability to for of our enrollment access for disease. This is trial completion. fistulas patients, with our of Phase the to patients comparison up autogenous and arteriovenous or in development AV to hemodialysis is in end-stage HAV trial
for HAV were the no of X in follow-up access and this dialysis expect a the on Results indication. of the to durability patients Based We filing built the period infection the during long-term top period BLA published a journal, with for be clinical Phase from of anticipate later showed follow-up followed reports line study, XXXX the usability in X Vascular immunogenicity. EJVES year or the by X-year trial into completed HAV the Forum. results we X-year dialysis enrollment data year. receiving
our As with insights and we Fresenius in strong kidney progress toward launch care Fresenius value-based commercialization, commercial and Care. Medical valuable our global we market look relationship partner to services, and building also advantages. care forward leader providing global upon in and is products shareholder, the
value propositions us We are with partnering care the evaluations Frenova, will the the evaluate kidney in both research health HAV cost vulnerable with Fresenius in of by of to group patients These U.S. assist a and Europe. access failure. models clinical development economic hemodialysis and for patients owned for with
progress other program make programs we conditions, arterial our Finally, indications. to are in such emergency with for HAVs in vascular patients earlier continuing peripheral portfolio as The severe access also expanded in presentation implanted first the were patients progress. X this in disease, cases we continues to of XX in January. And the outcomes U.S. program. roughly in the To-date, under highlighted have a
anticipate CABG. potential primate or presentation was HAVs a first small exhibited as PAD of January. non-human for the maintain the use HAVs advancing. the we patients programs, enrollment observed highlighting In providing of and bypass Clinic’s use year. we HAVs in our regeneration in artery an on patency addition, With treatment coronary of diameter later bypass remodeling to grafting results coronary Therapies this January, of to at presented in of This the And study, respect our study the Week update was preclinical HAV as grafting. in study In is from well this positive artery in for thus severe Advanced in our model, Mayo this study investigator-sponsored preclinical host
addition, organ by encouraged our HAVs In complex systems. efforts to in developing as we continue be
a and in rodent pancreas, is of BVP is forward preclinical diabetics. studies Type currently insulin or deliver designed And large biovascular moving are X that HAV were animal this with published results the year Engineering. to Journal into last we program. in eyelets Our BVP, model diabetic coated Tissue exciting to of an
to month, mentioned lead AstraZeneca. updates, than the experience last development As far leadership clinical us to Parikh led functions. development, Dr. affairs of Chief academia, pharmaceutical global as appointment global as our as Officer. earlier, safety more medical the product across clinical Medical his our strategy, XX-year brings clinical clinical and tenure two J. role, Parikh and oversight Parikh corporate therapeutic affairs pleased and and Shamik including in other his of announce Dr. decades of MD were the research areas. companies, including multiple medical and Dr. will NIH preclinical has new we drug development, Parikh launches, In operations I at
And team. Dr. turn with that, to to and insights are developments. with Parikh for pleased results Dale other review expertise have the very his us and we forward to for adding now are a Humacyte will and over I of financial We it to business looking our
